Did CEOs and officers buy or sell their own stock?
Open-market trades by the people who know the company best, with their own money.
Last 7 days: the stocks insiders bought and sold most
Stocks Koreans hold most · disclosed Last 7 days · open-market trades only
Bought most
Sold most
Whalegun
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
ImmunomeIMNM | Open-market sale10b5-1 plan | 06/25 | 06/29 | 55,000 sh2 trades | $19.85avg. | $1,091,662 | −77.7% | |
Max RosettCFO | ImmunomeIMNM | Open-market sale10b5-1 plan | 06/15 | 06/17 | 60,000 sh | $18.23 | $1,093,800 | −52.6% |
ImmunomeIMNM | Open-market buy | 06/05 | 06/09 | 10,500 sh3 trades | $19.45avg. | $204,260 | +31.9% | |
ImmunomeIMNM | Open-market sale | 06/05 | 06/09 | 10,500 sh2 trades | $19.41avg. | $203,820 | −24.2% | |
Jean Jacques BienaimeDirector | ImmunomeIMNM | Open-market buy | 05/15 | 05/19 | 5,000 sh | $20.70 | $103,500 | +13.0% |
Jack HigginsChief Scientific Officer | ImmunomeIMNM | Open-market sale10b5-1 plan | 04/02 | 04/03 | 9,438 sh | $21.64 | $204,238.32 | −30.0% |
ImmunomeIMNM | Open-market sale10b5-1 plan | 04/02 | 04/03 | 65,000 sh2 trades | $21.92avg. | $1,424,916.08 | −54.6% | |
Clay B. SiegallPresident and CEO | ImmunomeIMNM | Open-market buy | 03/27 | 03/31 | 25,450 sh | $19.67 | $500,601.5 | +3.8% |
ImmunomeIMNM | Open-market sale | 03/20–03/23 | 03/23 | 65,000 sh2 trades | $20.55avg. | $1,335,626 | −16.0% | |
ImmunomeIMNM | Open-market buy | 03/10–03/11 | 03/12 | 2,000 sh2 trades | $21.84avg. | $43,670 | +5.5% | |
Clay B. SiegallPresident and CEO | ImmunomeIMNM | Open-market buy | 25/12/30 | 25/12/30 | 4,729 sh | $21.15 | $100,018.35 | +0.7% |
ImmunomeIMNM | Open-market sale10b5-1 plan | 25/12/22 | 25/12/23 | 383,200 sh2 trades | $21.74avg. | $8,330,079.62 | −15.9% | |
Clay B. SiegallPresident and CEO | ImmunomeIMNM | Open-market buy | 25/12/19 | 25/12/22 | 7,278 sh | $20.48 | $149,053.44 | +0.9% |
Philip TsaiChief Technical Officer | ImmunomeIMNM | Open-market buy | 25/12/19 | 25/12/22 | 10,000 sh | $20.49 | $204,900 | +30.0% |
Clay B. SiegallPresident and CEO | ImmunomeIMNM | Open-market buy | 25/12/18 | 25/12/18 | 46,511 sh | $21.50 | $999,986.5 | +5.8% |
Jean Jacques BienaimeDirector | ImmunomeIMNM | Open-market buy | 25/06/03 | 25/06/03 | 5,000 sh | $9.38 | $46,900 | +15.9% |
Clay B. SiegallPresident and CEO | ImmunomeIMNM | Open-market buy | 25/03/26 | 25/03/26 | 137,100 sh | $7.29 | $999,459 | +20.5% |
Jean Jacques BienaimeDirector | ImmunomeIMNM | Open-market buy | 25/03/25 | 25/03/26 | 7,800 sh | $7.78 | $60,684 | +33.0% |
Jean Jacques BienaimeDirector | ImmunomeIMNM | Open-market buy | 25/03/24 | 25/03/25 | 7,000 sh | $8.21 | $57,470 | +42.1% |
Philip TsaiCTO | ImmunomeIMNM | Open-market buy | 25/03/24 | 25/03/25 | 12,300 sh | $8.42 | $103,566 | +58.6% |